Oxford BioMedical 2017/2018 lentiviral vector capacity expansion project

Oxford BioMedica is building a £6 million expansion of its UK manufacturing facility to produce more lentiviral vectors—the viral delivery vehicles used in gene and cell therapies. This matters because lentiviral vectors are essential for advanced treatments like CAR-T cell therapy, which reprograms a patient’s own immune cells to attack cancer. Kymriah, the only commercially approved therapy using this technology, relies on Oxford BioMedica’s vectors. But global demand for these therapies is growing faster than manufacturing capacity can keep up. Without more production space, patients may face delays or limited access to treatments. If this expansion succeeds, the UK will increase its high-value manufacturing capacity for advanced therapies, securing a leading position in a competitive global market. The project also promises to create highly skilled jobs and strengthen the supply chain for a technology that underpins a growing class of life-saving medicines. Most people will never see a lentiviral vector, but the therapies they enable could directly affect patients with certain cancers and genetic disorders.